Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on
October 25, 2011
ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) today announced that it will release third quarter
2011 financial results on Tuesday, October 25, 2011 after the close of the U.S.
financial markets. The Company will host a conference call and slide presentation
via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific
to discuss results and highlights of the third quarter, as well as current
corporate developments.
Conference call details:
Date:Tuesday, October 25, 2011
Time:4:30 p.m. ET
Dial-in (U.S.):877-941-1465
Dial-in (International): 480-629-9643
Web cast:http://www.questcor.com
To access an audio replay of the call:
Replay (U.S.):800-406-7325
Replay (International): 303-590-3030
Replay Passcode:4480054
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary
product helps patients with serious, difficult-to-treat medical conditions.
Questcor's primary product is H.P. Acthar? Gel (repository corticotropin
injection), an injectable drug that is approved by the FDA for the treatment of
19 indications. Of these 19 indications, Questcor currently generates
substantially all of its net sales from three indications: the treatment of acute
exacerbations of multiple sclerosis in adults, the treatment of infantile spasms
in children under two years of age and the treatment of nephrotic syndrome.
Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to
"induce a diuresis or a remission of proteinuria in the nephrotic syndrome
without uremia of the idiopathic type or that due to lupus erythematosus."
Questcor is also exploring the possibility of developing markets for other
on-label indications and pursuing FDA approval of additional indications not
currently on the Acthar label where there is high unmet medical need. Questcor
also markets Doral(R) (quazepam), which is indicated for the treatment of
insomnia characterized by difficulty in falling asleep, frequent nocturnal
awakenings, and/or early morning awakenings. For more information, please visit
questcor.com. |
